Latest News
Telix Pharmaceuticals Acquires TheraPharm to Expand Hemotology Diagnostic and Therapeutic Solutions
Monday 30 November 2020

Australian biopharmaceutical company Telix Pharmaceuticals Ltd. (ASX: TLX) has agreed to acquire Swiss/German biotechnology company TheraPharm GmbH from Scintec Diagnostics GmbH to broaden reach to hematologic cancers and transplant medicine, the company said.

Telix will acquire TheraPham for an upfront payment of EUR 10.2m (AUD 16.5m) (USD 12.2m).

The acquisition of TheraPharm provides Telix with access to a portfolio of patents, technologies, production systems, clinical data and know-how in relation to the use of Molecularly Targeted Radiation in hematology and immunology.

Telix Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focussed on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation.

TheraPharm GmbH is a biotechnology company specialised in the research, development and manufacturing of monoclonal antibodies for targeted radiation of hematopoietic malignant and non-malignant diseases, lymphoproliferative diseases, conditioning for allogeneic stem cells as well as in diagnostics of inflammatory diseases and bone marrow metastases.
Date Published: 30/11/2020